Form 8-K - Current report:
SEC Accession No. 0001628280-24-042602
Filing Date
2024-10-09
Accepted
2024-10-09 16:04:35
Documents
16
Period of Report
2024-10-03
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20241003.htm   iXBRL 8-K 28425
2 EX-10.1 exhibit101-ardelyxxlease.htm EX-10.1 537511
3 EX-10.2 exhibit102-ardenwoodxardel.htm EX-10.2 32125
7 ardx-20241003_g1.jpg GRAPHIC 2570
  Complete submission text file 0001628280-24-042602.txt   845653

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20241003.xsd EX-101.SCH 1901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20241003_lab.xml EX-101.LAB 22548
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20241003_pre.xml EX-101.PRE 13046
19 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20241003_htm.xml XML 2376
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 241362825
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)